Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported a strong Q2 2026 financial update highlighting encouraging Phase 1/2 clinical data for its cancer drug vopimetostat in combination with daraxonrasib for MTAP-deleted, RAS-mutant pancreatic cancer. The combination achieved a 92% objective response rate and 90% six-month progression-free survival, positioning it for late-s…